Citations (112)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Christopher B. Lietz, Ekaterina Deyanova, Younhee Cho, Jon Cordia, Sarah Franc, Sally Kabro, Steven Wang, David Mikolon & Douglas D. Banks. (2023) Identification of tyrosine sulfation in the variable region of a bispecific antibody and its effect on stability and biological activity. mAbs 15:1.
Read now
Read now
Dario A. T. Cramer, Vojtech Franc, Anna-Katharina Heidenreich, Michaela Hook, Mahdi Adibzadeh, Dietmar Reusch, Albert J. R. Heck & Markus Haberger. (2023) Characterization of high-molecular weight by-products in the production of a trivalent bispecific 2+1 heterodimeric antibody. mAbs 15:1.
Read now
Read now
Gabrielle Leclercq, Llucia Alberti Servera, Sabrina Danilin, John Challier, Nathalie Steinhoff, Claudia Bossen, Alex Odermatt, Valeria Nicolini, Pablo Umaña, Christian Klein, Marina Bacac, Anna-Maria Giusti, Anneliese Schneider & Hélène Haegel. (2022) Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils. OncoImmunology 11:1.
Read now
Read now
Dennis J. Underwood, Jeffrey Bettencourt & Zahra Jawad. (2022) The manufacturing considerations of bispecific antibodies. Expert Opinion on Biological Therapy 22:8, pages 1043-1065.
Read now
Read now
Eugenia Opolka-Hoffmann, Gregor Jordan, Michael Otteneder, Robin Kieferle, Martin Lechmann, Gerhard Winter & Roland F. Staack. (2021) The impact of immunogenicity on therapeutic antibody pharmacokinetics: A preclinical evaluation of the effect of immune complex formation and antibody effector function on clearance. mAbs 13:1.
Read now
Read now
Marlena Surowka, Wolfgang Schaefer & Christian Klein. (2021) Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins. mAbs 13:1.
Read now
Read now
Oksana Tyshchuk, Christoph Gstöttner, Dennis Funk, Simone Nicolardi, Stefan Frost, Stefan Klostermann, Tim Becker, Elena Jolkver, Felix Schumacher, Claudia Ferrara Koller, Hans Rainer Völger, Manfred Wuhrer, Patrick Bulau & Michael Mølhøj. (2019) Characterization and prediction of positional 4-hydroxyproline and sulfotyrosine, two post-translational modifications that can occur at substantial levels in CHO cells-expressed biotherapeutics. mAbs 11:7, pages 1219-1232.
Read now
Read now
Irma Herrera-Camacho, Maricruz Anaya-Ruiz, Martin Perez-Santos, Lourdes Millán-Pérez Peña, Cindy Bandala & Gerardo Landeta. (2019) Cancer immunotherapy using anti-TIM3/PD-1 bispecific antibody: a patent evaluation of EP3356411A1. Expert Opinion on Therapeutic Patents 29:8, pages 587-593.
Read now
Read now
Marie Godar, Hans de Haard, Christophe Blanchetot & Jacobus Rasser. (2018) Therapeutic bispecific antibody formats: a patent applications review (1994-2017). Expert Opinion on Therapeutic Patents 28:3, pages 251-276.
Read now
Read now
Mariona Cabo, Rienk Offringa, Laurence Zitvogel, Guido Kroemer, Aura Muntasell & Lorenzo Galluzzi. (2017) Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications. OncoImmunology 6:12.
Read now
Read now
Jörg Moelleken, Manuel Endesfelder, Christian Gassner, Sabine Lingke, Simone Tomaschek, Oksana Tyshchuk, Stefan Lorenz, Ulrike Reiff & Michael Mølhøj. (2017) GingisKHAN™ protease cleavage allows a high-throughput antibody to Fab conversion enabling direct functional assessment during lead identification of human monoclonal and bispecific IgG1 antibodies. mAbs 9:7, pages 1076-1087.
Read now
Read now
Shiyong Gong, Fang Ren, Danqing Wu, Xuan Wu & Chengbin Wu. (2017) Fabs-in-tandem immunoglobulin is a novel and versatile bispecific design for engaging multiple therapeutic targets. mAbs 9:7, pages 1118-1128.
Read now
Read now
Claudia A. Castro Jaramillo, Sara Belli, Anne-Christine Cascais, Sherri Dudal, Martin R. Edelmann, Markus Haak, Marie-Elise Brun, Michael B. Otteneder, Mohammed Ullah, Christoph Funk, Franz Schuler & Silke Simon. (2017) Toward in vitro-to-in vivo translation of monoclonal antibody pharmacokinetics: Application of a neonatal Fc receptor-mediated transcytosis assay to understand the interplaying clearance mechanisms. mAbs 9:5, pages 781-791.
Read now
Read now
Ulrich Brinkmann & Roland E. Kontermann. (2017) The making of bispecific antibodies. mAbs 9:2, pages 182-212.
Read now
Read now
Articles from other publishers (98)
Xiaohan Guo, Yi Wu, Ying Xue, Na Xie & Guobo Shen. (2023) Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment. Frontiers in Immunology 14.
Crossref
Crossref
Naoual Dahmana, Pierre-Louis Destruel, Samantha Facchetti, Vanessa Braun, Vanessa Lebouc, Zana Marin, Sulabh Patel & Gregoire Schwach. (2023) Reversible protein complexes as a promising avenue for the development of high concentration formulations of biologics. International Journal of Pharmaceutics 648, pages 123616.
Crossref
Crossref
Michael Chinn, Katharina Doninger, Ranya Al-Khaledy, Emily Zhang, Hakyoung Kim, Silke Werz & Florian Schelter. (2023) A comprehensive assessment of the applicability of RoboColumn as a chromatography scale-down model for use in biopharmaceutical process validation. Journal of Chromatography A 1710, pages 464391.
Crossref
Crossref
Matteo Righi, Isaac Gannon, Matthew Robson, Saket Srivastava, Evangelia Kokalaki, Thomas Grothier, Francesco Nannini, Christopher Allen, Yuchen V. Bai, James Sillibourne, Shaun Cordoba, Simon Thomas & Martin Pule. (2023) Enhancing CAR T-cell Therapy Using Fab-Based Constitutively Heterodimeric Cytokine Receptors. Cancer Immunology Research 11:9, pages 1203-1221.
Crossref
Crossref
Sameek Singh, Wenzhi Tian, Zachary C. Severance, Santosh K. Chaudhary, Viktoriya Anokhina, Basudeb Mondal, Rajaiah Pergu, Prashant Singh, Uttam Dhawa, Santanu Singha & Amit Choudhary. (2023) Proximity-inducing modalities: the past, present, and future. Chemical Society Reviews 52:16, pages 5485-5515.
Crossref
Crossref
Jing Zeng, Yalin Chen, Tingting Zhang, Jinjing Wang, Yan Yang & Yi Fang. (2023) Effect of a CrossMab cotargeting CD20 and HLA-DR in non-Hodgkin lymphoma. Oncologie 0:0.
Crossref
Crossref
Tanja Ziegengeist, Jennifer Orth, Katja Kroll, Marion Schneider, Nadja Spindler, Dilyana Dimova, Severin Handschuh, Arnd Brandenburg, Reto Ossola, Norbert Furtmann, Joerg Birkenfeld, Christian Beil, Dietmar Hoffmann, Thorsten Schmidt, Rebecca Sendak, Melanie Fischer, Soraya Hölper & Jennifer Kühn. (2023) High-Throughput and Format-Agnostic Mispairing Assay for Multispecific Antibodies Using Intact Mass Spectrometry. Analytical Chemistry 95:27, pages 10265-10278.
Crossref
Crossref
Claudia Lange, Reimo Tetzner, Tobias Strunz & Kay D. Rittenhouse. (2023) Aflibercept Suppression of Angiopoietin-2 in a Rabbit Retinal Vascular Hyperpermeability Model. Translational Vision Science & Technology 12:5, pages 17.
Crossref
Crossref
Ruixiang Wang & Peng Zou. (2023) Bioorthogonal Chemical Ligation Creates Synthetic Antibodies with Improved Therapeutic Potency. ACS Central Science 9:3, pages 349-351.
Crossref
Crossref
Fabien Thoreau, Peter A. Szijj, Michelle K. GreeneLéa N. C. RochetIoanna A. ThanasiJaine K. BlayneyAntoine MaruaniJames R. Baker, Christopher J. ScottVijay Chudasama. (2023) Modular Chemical Construction of IgG-like Mono- and Bispecific Synthetic Antibodies (SynAbs). ACS Central Science 9:3, pages 476-487.
Crossref
Crossref
Wanying Wang, Tianyu Qiu, Fei LiShengxiang Ren. (2023) Current status and future perspectives of bispecific antibodies in the treatment of lung cancer. Chinese Medical Journal 136:4, pages 379-393.
Crossref
Crossref
Aaron T. Wecksler, Victor Lundin, Ambrose J. Williams, Karthik Veeravalli, Dorothea E. Reilly & Sung-Hye Grieco. (2023) Bioprocess Development and Characterization of a 13C-Labeled Hybrid Bispecific Antibody Produced in Escherichia coli. Antibodies 12:1, pages 16.
Crossref
Crossref
Lorenzo Falchi, Santosha A. Vardhana & Gilles A. Salles. (2023) Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities. Blood 141:5, pages 467-480.
Crossref
Crossref
Steffen Lippold, Michaela Hook, Christian Spick, Alexander Knaupp, Kevin Whang, Fabian Ruperti, Lance Cadang, Nisana Andersen, Annette Vogt, Michael Grote, Dietmar Reusch, Markus Haberger, Feng Yang & Tilman Schlothauer. (2023) CD3 Target Affinity Chromatography Mass Spectrometry as a New Tool for Function–Structure Characterization of T-Cell Engaging Bispecific Antibody Proteoforms and Product-Related Variants. Analytical Chemistry 95:4, pages 2260-2268.
Crossref
Crossref
Mohsin Bilal, Mohammed Nimir, David Snead, Graham S. Taylor & Nasir Rajpoot. (2022) Role of AI and digital pathology for colorectal immuno-oncology. British Journal of Cancer 128:1, pages 3-11.
Crossref
Crossref
Felix Seelinger, Felix Wittkopp, Thomas von Hirschheydt & Christian Frech. (2023) Anti-Langmuir elution behavior of a bispecific monoclonal antibody in cation exchange chromatography: Mechanistic modeling using a pH-dependent Self-Association Steric Mass Action isotherm. Journal of Chromatography A 1689, pages 463730.
Crossref
Crossref
Wolfgang Koehnlein, Annika Holzgreve, Klaus Schwendner, Romas Skudas & Florian Schelter. (2023) Purification of hydrophobic complex antibody formats using a moderately hydrophobic mixed mode cation exchange resin. Journal of Chromatography A 1687, pages 463696.
Crossref
Crossref
Pooya Farhangnia, Ali-Akbar Delbandi, Maryam Sadri & Mahzad Akbarpour. 2022. Handbook of Cancer and Immunology. Handbook of Cancer and Immunology
1
46
.
Shrestha Dutta, Swatilekha Ghosh, Abhishek Mishra & Rajgourab Ghosh. (2022) Oncoproteomics: insight into current proteomic technologies in cancer biomarker discovery and treatment. Journal of Proteins and Proteomics.
Crossref
Crossref
Stefania C. Carrara, Julia Harwardt, Julius Grzeschik, Björn Hock & Harald Kolmar. (2022) TriTECM: A tetrafunctional T-cell engaging antibody with built-in risk mitigation of cytokine release syndrome. Frontiers in Immunology 13.
Crossref
Crossref
Martin R. Edelmann. (2022) Radiolabelling small and biomolecules for tracking and monitoring. RSC Advances 12:50, pages 32383-32400.
Crossref
Crossref
Mohsen Karami Fath, Jalil Azami, Alireza Masoudi, Reza Mosaddeghi Heris, Elnaz Rahmani, Fatemeh Alavi, Armina Alagheband Bahrami, Zahra Payandeh, Bahman Khalesi, Masoomeh Dadkhah, Navid Pourzardosht & Vahideh Tarhriz. (2022) Exosome-based strategies for diagnosis and therapy of glioma cancer. Cancer Cell International 22:1.
Crossref
Crossref
Sławomir Liberski, Małgorzata Wichrowska & Jarosław Kocięcki. (2022) Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review. International Journal of Molecular Sciences 23:16, pages 9424.
Crossref
Crossref
Bo Wang, Jun Lin, Matthew R Hoag, Meredith Wright, Mingjun Ma, Wenyan Cai, Sachith Gallolu Kankanamalage & Yue Liu. (2022) A novel IgG Fc by computer-aided design enhances heavy-chain heterodimerization in bi- or trispecific antibodies. Antibody Therapeutics 5:3, pages 216-225.
Crossref
Crossref
Felix Seelinger, Felix Wittkopp, Thomas von Hirschheydt & Christian Frech. (2022) Application of the Steric Mass Action formalism for modeling under high loading conditions: Part 2. Investigation of high loading and column overloading effects. Journal of Chromatography A 1676, pages 463266.
Crossref
Crossref
Felix Seelinger, Felix Wittkopp, Thomas von Hirschheydt, Mathias Hafner & Christian Frech. (2022) Application of the Steric Mass Action formalism for modeling under high loading conditions: Part 1. Investigation of the influence of pH on the steric shielding factor. Journal of Chromatography A 1676, pages 463265.
Crossref
Crossref
Shiyu Qi, Shoulong Deng, Zhengxing Lian & Kun Yu. (2022) Novel Drugs with High Efficacy against Tumor Angiogenesis. International Journal of Molecular Sciences 23:13, pages 6934.
Crossref
Crossref
Jia‐Yi Ma, Ya‐Xin Wang, Yan Huang, Yi Zhang, Yun‐Xi Cui & De‐Ming Kong. (2022) Chemical–biological approaches for the direct regulation of cell–cell aggregation. Aggregate 3:2.
Crossref
Crossref
Fabien Thoreau & Vijay Chudasama. (2022) Enabling the next steps in cancer immunotherapy: from antibody-based bispecifics to multispecifics, with an evolving role for bioconjugation chemistry. RSC Chemical Biology 3:2, pages 140-169.
Crossref
Crossref
Edurne Rujas, Hong Cui, Jonathan Burnie, Clare Burn Aschner, Tiantian Zhao, Sara Insausti, Krithika Muthuraman, Anthony Semesi, Jasper Ophel, Jose L. Nieva, Michael S. Seaman, Christina Guzzo, Bebhinn Treanor & Jean-Philippe Julien. (2022) Engineering pan–HIV-1 neutralization potency through multispecific antibody avidity. Proceedings of the National Academy of Sciences 119:4.
Crossref
Crossref
Susanne PageTarik KhanPeter KühlGregoire SchwachKirsten Storch & Hitesh Chokshi. (2022) Patient Centricity Driving Formulation Innovation: Improvements in Patient Care Facilitated by Novel Therapeutics and Drug Delivery Technologies. Annual Review of Pharmacology and Toxicology 62:1, pages 341-363.
Crossref
Crossref
Gabrielle Leclercq, Hélène Haegel, Alberto Toso, Tina Zimmermann, Luke Green, Nathalie Steinhoff, Johannes Sam, Vesna Pulko, Anneliese Schneider, Anna Maria Giusti, John Challier, Anne Freimoser-Grundschober, Laurent Larivière, Alex Odermatt, Martin Stern, Pablo Umana, Marina Bacac & Christian Klein. (2022) JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy. Journal for ImmunoTherapy of Cancer 10:1, pages e003766.
Crossref
Crossref
Sami El Khatib & Mohamed Salla. (2022) The mosaic puzzle of the therapeutic monoclonal antibodies and antibody fragments - A modular transition from full-length immunoglobulins to antibody mimetics. Leukemia Research Reports 18, pages 100335.
Crossref
Crossref
John S. Schardt, Harkamal S. Jhajj, Ryen L. O'Meara, Timon S. Lwo, Matthew D. Smith & Peter M. Tessier. (2022) Agonist antibody discovery: Experimental, computational, and rational engineering approaches. Drug Discovery Today 27:1, pages 31-48.
Crossref
Crossref
Patty A. Culp, Jeremiah D. Degenhardt, Danielle E. Dettling & Chad May. 2022. Cancer Immunology and Immunotherapy. Cancer Immunology and Immunotherapy
267
319
.
Pamela D. Garzone & Yow-Ming C. Wang. 2022. Atkinson's Principles of Clinical Pharmacology. Atkinson's Principles of Clinical Pharmacology
611
651
.
Yue Du & Jian Xu. (2021) Engineered Bifunctional Proteins for Targeted Cancer Therapy: Prospects and Challenges. Advanced Materials 33:48.
Crossref
Crossref
Farideh Ghalamfarsa, Seyyed Hossein Khatami, Omid Vakili, Mortaza Taheri-Anganeh, Amir Tajbakhsh, Amir Savardashtaki, Yousef Fazli, Leila Rezaei Uonaki, Zahra Shabaninejad, Ahmad Movahedpour & Ghasem Ghalamfarsa. (2021) Bispecific antibodies in colorectal cancer therapy: recent insights and emerging concepts. Immunotherapy 13:16, pages 1355-1367.
Crossref
Crossref
Racheal Grace Akwii & Constantinos M. Mikelis. (2021) Targeting the Angiopoietin/Tie Pathway: Prospects for Treatment of Retinal and Respiratory Disorders. Drugs 81:15, pages 1731-1749.
Crossref
Crossref
Lucía Gandullo-Sánchez, Alberto Ocaña & Atanasio Pandiella. (2021) Generation of Antibody-Drug Conjugate Resistant Models. Cancers 13:18, pages 4631.
Crossref
Crossref
Lu Shan, Nydia Van Dyk, Nantaporn Haskins, Kimberly M. Cook, Kim L. Rosenthal, Ronit Mazor, Sonia Dragulin-Otto, Yu Jiang, Herren Wu, William F. Dall’Acqua, Martin J. Borrok, Melissa M. Damschroder & Vaheh Oganesyan. (2021) In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance. Communications Biology 4:1.
Crossref
Crossref
Gabrielle Leclercq, Hélène Haegel, Anneliese Schneider, Anna Maria Giusti, Estelle Marrer-Berger, Christophe Boetsch, Antje-Christine Walz, Vesna Pulko, Johannes Sam, John Challier, Cristiano Ferlini, Alex Odermatt, Pablo Umaña, Marina Bacac & Christian Klein. (2021) Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies. Journal for ImmunoTherapy of Cancer 9:7, pages e002582.
Crossref
Crossref
Huilin Yang, Yun‐Huai Kuo, Zion I. Smith & Jamie Spangler. (2021) Targeting cancer metastasis with antibody therapeutics. WIREs Nanomedicine and Nanobiotechnology 13:4.
Crossref
Crossref
Mariam Elshiaty, Hannah Schindler & Petros Christopoulos. (2021) Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer. International Journal of Molecular Sciences 22:11, pages 5632.
Crossref
Crossref
Jan P. Bogen, Stefania C. Carrara, David Fiebig, Julius Grzeschik, Björn Hock & Harald Kolmar. (2021) Design of a Trispecific Checkpoint Inhibitor and Natural Killer Cell Engager Based on a 2 + 1 Common Light Chain Antibody Architecture. Frontiers in Immunology 12.
Crossref
Crossref
Jiabing Ma, Yicheng Mo, Menglin Tang, Junjie Shen, Yanan Qi, Wenxu Zhao, Yi Huang, Yanmin Xu & Cheng Qian. (2021) Bispecific Antibodies: From Research to Clinical Application. Frontiers in Immunology 12.
Crossref
Crossref
Jing Shi, Xuesong Chen, Jianbo Diao, Liying Jiang, Lan Li, Stephen Li, Wenzhong Liang, Xiaoying Jin, Yonghui Wang, Colton Wong, Xiaolong Tom Zhang & Francis L.S. Tse. (2021) Bioanalysis in the Age of New Drug Modalities. The AAPS Journal 23:3.
Crossref
Crossref
Seil Jang, Jaeho Song, NaYoung Kim, Jeonghyeon Bak, Keehoon Jung, Young Woo Park, Bum-Chan Park & Ho Min Kim. (2021) Development of an antibody-like T-cell engager based on VH-VL heterodimer formation and its application in cancer therapy. Biomaterials 271, pages 120760.
Crossref
Crossref
Seyed Samad Hosseini, Saeed Khalili, Behzad Baradaran, Negar Bidar, Mohammad-Ali Shahbazi, Jafar Mosafer, Mahmoud Hashemzaei, Ahad Mokhtarzadeh & Michael R. Hamblin. (2021) Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials. International Journal of Biological Macromolecules 167, pages 1030-1047.
Crossref
Crossref
Tobias Graf, Michael Leiss, Markus Haberger & Patrick Bulau. 2021. Monoclonal Antibodies. Monoclonal Antibodies
199
234
.
Samvedna Saini & Yatender Kumar. 2021. Translational Biotechnology. Translational Biotechnology
233
266
.
Christoph Gstöttner, Simone Nicolardi, Markus Haberger, Dietmar Reusch, Manfred Wuhrer & Elena Domínguez-Vega. (2020) Intact and subunit-specific analysis of bispecific antibodies by sheathless CE-MS. Analytica Chimica Acta 1134, pages 18-27.
Crossref
Crossref
Jason Neidleman, Xiaoyu Luo, Julie Frouard, Guorui Xie, Feng Hsiao, Tongcui Ma, Vincent Morcilla, Ashley Lee, Sushama Telwatte, Reuben Thomas, Whitney Tamaki, Benjamin Wheeler, Rebecca Hoh, Ma Somsouk, Poonam Vohra, Jeffrey Milush, Katherine Sholtis James, Nancie M Archin, Peter W Hunt, Steven G Deeks, Steven A Yukl, Sarah Palmer, Warner C Greene & Nadia R Roan. (2020) Phenotypic analysis of the unstimulated in vivo HIV CD4 T cell reservoir. eLife 9.
Crossref
Crossref
Tobias Graf, Katrin Heinrich, Ingrid Grunert, Harald Wegele, Markus Haberger, Patrick Bulau & Michael Leiss. (2020) Recent advances in LC–MS based characterization of protein-based bio-therapeutics – mastering analytical challenges posed by the increasing format complexity. Journal of Pharmaceutical and Biomedical Analysis 186, pages 113251.
Crossref
Crossref
Noelia Blanco, Ambrose J. Williams, Danming Tang, Dejin Zhan, Shahram Misaghi, Robert F. Kelley & Laura C. Simmons. (2020) Tailoring translational strength using Kozak sequence variants improves bispecific antibody assembly and reduces product‐related impurities in CHO cells. Biotechnology and Bioengineering 117:7, pages 1946-1960.
Crossref
Crossref
Josée Golay & Alain E. Andrea. (2020) Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies. Antibodies 9:2, pages 17.
Crossref
Crossref
Dennis R. Goulet, Adam Zwolak, James A. Williams, Mark L. Chiu & William M. Atkins. (2019) Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors. Proteins: Structure, Function, and Bioinformatics 88:5, pages 689-697.
Crossref
Crossref
Julien Camperi, Davy Guillarme, Ming Lei & Cinzia Stella. (2020) Automated middle-up approach for the characterization of biotherapeutic products by combining on-line hinge-specific digestion with RPLC-HRMS analysis. Journal of Pharmaceutical and Biomedical Analysis 182, pages 113130.
Crossref
Crossref
Aerin Yoon, Shinai Lee, Sua Lee, Sojung Lim, Yong-Yea Park, Eunjung Song, Dong-Sik Kim, Kisu Kim & Yangmi Lim. (2020) A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors. Biomolecules 10:3, pages 399.
Crossref
Crossref
Janine Hauschildt, Claudia Schrimpf, Kristina Thamm, Jennifer Retzlaff, Temitayo O. Idowu, Constantin von Kaisenberg, Hermann Haller & Sascha David. (2020) Dual Pharmacological Inhibition of Angiopoietin-2 and VEGF-A in Murine Experimental Sepsis. Journal of Vascular Research 57:1, pages 34-45.
Crossref
Crossref
Dennis R. Goulet & William M. Atkins. (2020) Considerations for the Design of Antibody-Based Therapeutics. Journal of Pharmaceutical Sciences 109:1, pages 74-103.
Crossref
Crossref
Chen Gu & Diego Ellerman. 2020. Development of Biopharmaceutical Drug-Device Products. Development of Biopharmaceutical Drug-Device Products
71
90
.
James Steinhardt, Yanli Wu, Ryan Fleming, Ben T. Ruddle, Pooja Patel, Herren Wu, Changshou Gao & Nazzareno Dimasi. (2019) Fab-Arm Exchange Combined with Selective Protein A Purification Results in a Platform for Rapid Preparation of Monovalent Bispecific Antibodies Directly from Culture Media. Pharmaceutics 12:1, pages 3.
Crossref
Crossref
Wilson Phung, Guanghui Han, Stéphanie G.I. Polderdijk, Michael Dillon, Whitney Shatz, Peter Liu, Bingchuan Wei, Pawankumar Suresh, David Fischer, Christoph Spiess, Aaron Bailey, Paul J. Carter, Jennie R. Lill & Wendy Sandoval. (2019) Characterization of bispecific and mispaired IgGs by native charge-variant mass spectrometry. International Journal of Mass Spectrometry 446, pages 116229.
Crossref
Crossref
Steffen Lippold, Simone Nicolardi, Manfred Wuhrer & David Falck. (2019) Proteoform-Resolved FcɤRIIIa Binding Assay for Fab Glycosylated Monoclonal Antibodies Achieved by Affinity Chromatography Mass Spectrometry of Fc Moieties. Frontiers in Chemistry 7.
Crossref
Crossref
A. G. Beck-Sickinger. (2019) Gerichtete Evolution in der Wirkstoff- und AntikörperentwicklungDirected evolution in drug and antibody development. Der Internist 60:10, pages 1014-1020.
Crossref
Crossref
Diana Darowski, Christian Jost, Kay Stubenrauch, Uwe Wessels, Jörg Benz, Andreas Ehler, Anne Freimoser-Grundschober, Peter Brünker, Ekkehard Mössner, Pablo Umaña, Sebastian Kobold & Christian Klein. (2019) P329G-CAR-J: a novel Jurkat-NFAT-based CAR-T reporter system recognizing the P329G Fc mutation. Protein Engineering, Design and Selection.
Crossref
Crossref
Frans V. Suurs, Marjolijn N. Lub-de Hooge, Elisabeth G.E. de Vries & Derk Jan A. de Groot. (2019) A review of bispecific antibodies and antibody constructs in oncology and clinical challenges. Pharmacology & Therapeutics 201, pages 103-119.
Crossref
Crossref
Eugenia Hoffmann, Gregor Jordan, Matthias Lauer, Philippe Ringler, Eric A. Kusznir, Arne C. Rufer, Sylwia Huber, Anton Jochner, Gerhard Winter & Roland F. Staack. (2019) Generation, Characterization, and Quantitative Bioanalysis of Drug/Anti-drug Antibody Immune Complexes to Facilitate Dedicated In Vivo Studies. Pharmaceutical Research 36:9.
Crossref
Crossref
Qiong Wang, Yiqun Chen, Jaeyoung Park, Xiao Liu, Yifeng Hu, Tiexin Wang, Kevin McFarland & Michael J. Betenbaugh. (2019) Design and Production of Bispecific Antibodies. Antibodies 8:3, pages 43.
Crossref
Crossref
Aran F. Labrijn, Maarten L. Janmaat, Janice M. Reichert & Paul W. H. I. Parren. (2019) Bispecific antibodies: a mechanistic review of the pipeline. Nature Reviews Drug Discovery 18:8, pages 585-608.
Crossref
Crossref
Jorick J. Bruins, Criss van de Wouw, Koen Wagner, Lina Bartels, Bauke Albada & Floris L. van Delft. (2019) Highly Efficient Mono-Functionalization of Knob-in-Hole Antibodies with Strain-Promoted Click Chemistry. ACS Omega 4:7, pages 11801-11807.
Crossref
Crossref
Strohl & Naso. (2019) Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells. Antibodies 8:3, pages 41.
Crossref
Crossref
Rihong Zhou, Shijing Wang, Hui Wen, Min Wang & Min Wu. (2019) The bispecific antibody HB-32, blockade of both VEGF and DLL4 shows potent anti-angiogenic activity in vitro and anti-tumor activity in breast cancer xenograft models. Experimental Cell Research 380:2, pages 141-148.
Crossref
Crossref
Kate L. Lowe, David Cole, Rupert Kenefeck, Ita OKelly, Marco Lepore & Bent K. Jakobsen. (2019) Novel TCR-based biologics: mobilising T cells to warm ‘cold’ tumours. Cancer Treatment Reviews 77, pages 35-43.
Crossref
Crossref
M. Messaoudene, T.P. Mourikis, J. Michels, Y. Fu, M. Bonvalet, M. Lacroix-Trikki, B. Routy, A. Fluckiger, S. Rusakiewicz, M.P. Roberti, S. Cotteret, C. Flament, V. Poirier-Colame, N. Jacquelot, F. Ghiringhelli, A. Caignard, A.M.M. Eggermont, G. Kroemer, A. Marabelle, M. Arnedos, C. Vicier, S. Dogan, F. Jaulin, S -J Sammut, W. Cope, C. Caldas, S. Delaloge, N. McGranahan, F. André & L. Zitvogel. (2019) T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants. Annals of Oncology 30:6, pages 934-944.
Crossref
Crossref
Jens C Göpfert, Astrid Reiser, Viviana A Carcamo Yañez, Annelie Pohle, Uwe Wessels, Anne Heine, Thomas O Joos, Corinne Petit-Frère, Everson Nogoceke & Kay-Gunnar Stubenrauch. (2019) Development and evaluation of an ultrasensitive free VEGF-A immunoassay for analysis of human aqueous humor. Bioanalysis 11:9, pages 875-886.
Crossref
Crossref
Honghui Zhou & Diane R. MouldPradeep B. Lukka, Santosh Wagh & Bernd Meibohm. 2019. Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune‐Mediated Inflammatory Diseases. Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune‐Mediated Inflammatory Diseases
187
208
.
Gergely Solecki, Matthias Osswald, Daniel Weber, Malte Glock, Miriam Ratliff, Hans-Joachim Müller, Oliver Krieter, Yvonne Kienast, Wolfgang Wick & Frank Winkler. (2019) Differential Effects of Ang-2/VEGF-A Inhibiting Antibodies in Combination with Radio- or Chemotherapy in Glioma. Cancers 11:3, pages 314.
Crossref
Crossref
Christian Klein, Wolfgang Schaefer, Joerg T. Regula, Charles Dumontet, Ulrich Brinkmann, Marina Bacac & Pablo Umaña. (2019) Engineering therapeutic bispecific antibodies using CrossMab technology. Methods 154, pages 21-31.
Crossref
Crossref
Xiufeng Wu & Stephen J. Demarest. (2019) Building blocks for bispecific and trispecific antibodies. Methods 154, pages 3-9.
Crossref
Crossref
Shiyong Gong & Chengbin Wu. (2019) Generation of Fabs-in-tandem immunoglobulin molecules for dual-specific targeting. Methods 154, pages 87-92.
Crossref
Crossref
Natalia Gomez, Agatha Wieczorek, Fang Lu, Richele Bruno, Luis Diaz, Neeraj J. Agrawal & Kristi Daris. (2018) Culture temperature modulates half antibody and aggregate formation in a Chinese hamster ovary cell line expressing a bispecific antibody. Biotechnology and Bioengineering 115:12, pages 2930-2940.
Crossref
Crossref
Bushra Husain & Diego Ellerman. (2018) Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies. BioDrugs 32:5, pages 441-464.
Crossref
Crossref
Mathias Kahl, Florian Settele, Paul Knick, Ulrich Haupts & Eva Bosse-Doenecke. (2018) Mabfilin and Fabfilin - New antibody-scaffold fusion formats for multispecific targeting concepts. Protein Expression and Purification 149, pages 51-65.
Crossref
Crossref
Sebastian Kobold, Stanislav Pantelyushin, Felicitas Rataj & Johannes vom Berg. (2018) Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy. Frontiers in Oncology 8.
Crossref
Crossref
Joerg Thomas Regula, Sabine Imhof-Jung, Michael Mølhøj, Joerg Benz, Andreas Ehler, Alexander Bujotzek, Wolfgang Schaefer & Christian Klein. (2018) Variable heavy–variable light domain and Fab-arm CrossMabs with charged residue exchanges to enforce correct light chain assembly. Protein Engineering, Design and Selection 31:7-8, pages 289-299.
Crossref
Crossref
Anuradha Krishnamurthy & Antonio Jimeno. (2018) Bispecific antibodies for cancer therapy: A review. Pharmacology & Therapeutics 185, pages 122-134.
Crossref
Crossref
Paul J. Carter & Greg A. Lazar. (2017) Next generation antibody drugs: pursuit of the 'high-hanging fruit'. Nature Reviews Drug Discovery 17:3, pages 197-223.
Crossref
Crossref
Petra Verdino, Shane Atwell & Stephen J Demarest. (2018) Emerging trends in bispecific antibody and scaffold protein therapeutics. Current Opinion in Chemical Engineering 19, pages 107-123.
Crossref
Crossref
James J. Steinhardt, Javier Guenaga, Hannah L. Turner, Krisha McKee, Mark K. Louder, Sijy O’Dell, Chi-I Chiang, Lin Lei, Andrey Galkin, Alexander K. Andrianov, Nicole A. Doria-Rose, Robert T. Bailer, Andrew B. Ward, John R. Mascola & Yuxing Li. (2018) Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity. Nature Communications 9:1.
Crossref
Crossref
Chantal Mengus, Manuele G. Muraro, Valentina Mele, Francesca Amicarella, Celeste Manfredonia, Federica Foglietta, Simone Muenst, Savas D. Soysal, Giandomenica Iezzi & Giulio C. Spagnoli. (2017) In Vitro Modeling of Tumor–Immune System Interaction. ACS Biomaterials Science & Engineering 4:2, pages 314-323.
Crossref
Crossref
Günter Jagschies. 2018. Biopharmaceutical Processing. Biopharmaceutical Processing
59
72
.
Laurence Fayadat-Dilman. 2018. Development of Antibody-Based Therapeutics. Development of Antibody-Based Therapeutics
133
160
.
Chien-Hsing Chang, Yang Wang, Rongxiu Li, Diane L. Rossi, Donglin Liu, Edmund A. Rossi, Thomas M. Cardillo & David M. Goldenberg. (2017) Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells. Cancer Research 77:19, pages 5384-5394.
Crossref
Crossref
Darko Skegro, Cian Stutz, Romain Ollier, Emelie Svensson, Paul Wassmann, Florence Bourquin, Thierry Monney, Sunitha Gn & Stanislas Blein. (2017) Immunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodies. Journal of Biological Chemistry 292:23, pages 9745-9759.
Crossref
Crossref
D. Hendriks, G. Choi, M. de Bruyn, V.R. Wiersma & E. Bremer. 2017.
289
383
.
Ji-Hee Ha, Jung-Eun Kim & Yong-Sung Kim. (2016) Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins. Frontiers in Immunology 7.
Crossref
Crossref